Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia.
The purpose of this study was to evaluate short-term adverse effects and determine a safe dosage for vinorelbine (Navelbine)--a new semisynthetic vinca alkaloid--in dogs with malignant tumors. Nineteen dogs were treated with vinorelbine as a 5-minute IV infusion every 7 days at starting dosages ranging from 10 to 20 mg/m2. The median number of treatments per dog was 7 (range, 1-11). The maximum tolerated dosage varied between 15 and 18 mg/m2, and a starting dosage of 15 mg/m2 is recommended. Neutropenia was the dose-limiting toxicity. Although efficacy was a secondary endpoint of this dosage-finding study, 2 dogs with metastatic bronchoalveolar carcinoma experienced a partial response for an overall response rate of 12.5% in 16 dogs with gross measurable disease. Three dogs with microscopic disease were treated (incompletely excised bronchoalveolar carcinoma or lymph node metastatic disease). Two died of pulmonary metastatic disease 113 and 196 days posttreatment, and 1 is still alive after at least 730 days. The well-tolerated toxicity profile and clinical activity observed in dogs with bronchoalveolar carcinoma warrants further investigation.
Department of Medical Sciences, University of Wisconsin, Madison, WI 53706, USA.
Valerie J
VJ
Poirier
Kristine E
KE
Burgess
William M
WM
Adams
David M
DM
Vail
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D004283:Dog Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D004285:Dogs; D005260:Female; D007262:Infusions, Intravenous / Q000662:veterinary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D011996:Records / Q000662:veterinary; D012189:Retrospective Studies; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D014922:Wisconsin / Q000453:epidemiology
D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D000077235:Vinorelbine